<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991286</url>
  </required_header>
  <id_info>
    <org_study_id>98-01-30-41687</org_study_id>
    <nct_id>NCT03991286</nct_id>
  </id_info>
  <brief_title>The Effect of Astaxanthin on Oxidative Stress Indices in Patients With Polycystic Ovary Syndrome</brief_title>
  <official_title>The Effect of Astaxanthin on Oxidative Stress Indices in Serum, and Induction of Signaling Pathways in Granulosa Cells in Patients With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of&#xD;
      reproductive age It is hypothesized that ∼20 fold increase in reactive oxygen species (ROS)&#xD;
      generation in Follicular fluid (FF) and granulosa cells of PCOS women plays an adverse role&#xD;
      in affecting the IVF success rate. Astaxanthin (3,3'-dihydroxy-β,β'-carotene-4,4'-dione) is a&#xD;
      nonprovitamin A carotenoid classified as a xanthophyll and is found in high amounts in the&#xD;
      red pigment of crustacean shells (e.g., crabs, shrimp), salmon, trout, and asteroides. It has&#xD;
      been demonstrated that astaxanthin displays a wide variety of biological activities,&#xD;
      including anti-oxidative, anticancer, and anti-inflammatory effects.&#xD;
&#xD;
      investigators aim to investigate the effect on Astaxanthin administrating on reducing of ROS&#xD;
      in FF and induction of antioxidant response elements in PCOS women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Actual">April 7, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum and follicular fluid oxidative stress biomarkers levels</measure>
    <time_frame>8 months</time_frame>
    <description>This parameter will measure using Enzyme-Linked. Immunosorbent Assays (ELISAs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>Day1(from the day of oocyte retrieval to fertilization confirmation)</time_frame>
    <description>using polarized light microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature(MII) oocyte</measure>
    <time_frame>Day1(from the day of oocyte retrieval to fertilization confirmation)</time_frame>
    <description>using polarized light microscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo&#xD;
Ovulatory Agent:&#xD;
Clomiphene Citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Astaxanthin 8mg&#xD;
Drug: Ovulatory Agent Clomiphene Citrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Astaxanthin 8 mg</intervention_name>
    <description>experimental</description>
    <arm_group_label>experimental</arm_group_label>
    <other_name>Algalife, Icelandic Astaxanthin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosed PCOS cases according to the National Institute of Health criteria (NIH consensus&#xD;
        criteria) and Rotterdam criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Menopause, pregnant or lactating females&#xD;
&#xD;
          -  individuals with diabetes&#xD;
&#xD;
          -  those with hepatic,renal, thyroid or cardiovascular disorders&#xD;
&#xD;
          -  patients with elevated levels of prolactin&#xD;
&#xD;
          -  those who were taking antioxidant supplements within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fardin Amidi, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Astaxanthin</keyword>
  <keyword>ROS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

